This is a new guideline from NICE, published in February, advising that dapagliflozin can now be used in heart failure.
Isn’t dapagliflozin for diabetes?
Yes it is. It is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It reduces glucose reabsorption in the kidneys.
As it does this, it also reduces sodium reabsorption. This increased excretion leads to an osmotic diuresis.